Pioneering pharmaceutical firm Vectura is planning to develop a centre of research and development excellence in Bristol as it looks for further global growth opportunities under new owner, tobacco group Philip Morris International (PMI).
This new sustainable, modern and fit-for-purpose R&D facility on the Bristol and Bath Science Park, will enable further growth for Vectura, providing new high-tech jobs for specialist respiratory scientists, lab technicians and respiratory device engineers. It will also provide the optimum environment for new innovation to support the development of important new treatments for patients.
In the South West region Bristol & Bath Science Park is recognised as a world-class environment providing the space, accessibility and support for science and technology businesses to accelerate their growth and success.
Vectura’s plans are available to view online at ice.vectura.com until February 28, with the public being invited to provide feedback in advance of a planning application being submitted to South Gloucestershire Council.
Once submitted, the full planning application will be available to view on the South Gloucestershire Council planning portal.
PMI, which makes Marlboro cigarettes, acquired Vectura despite a storm of protest from dozens of healthcare charities and public health bodies, including Asthma UK and the British Lung Foundation.
